Investigational drug combo for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of three drugs for people with advanced colorectal cancer that has not responded to previous treatments. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic colorectal cancer that has spread to other parts of the body.
- You are between 18 and 75 years old.
- You have tried at least two standard treatments, including oxaliplatin, irinotecan, and fluorouracil.
- Your liver tumors make up less than half of your liver.
- You have at least one measurable tumor that can be seen on a scan.
- Your organs are working well enough, based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination for people with advanced colorectal cancer that cannot be removed by surgery. It aims to see if the treatment can shrink tumors and help patients live longer.
This trial tests a combination of two targeted therapies (QL1706 and bevacizumab) plus standard chemotherapy for people with a specific form of metastatic colorectal cancer that has a BRAF V600E mutation and is MSS/pMMR. The goal is to see if this triplet works better than standard treatment alone.
This trial tests a new targeted drug (SHR-A1811) combined with chemotherapy and bevacizumab versus the usual therapy for advanced colorectal cancer that hasn't been treated yet. It aims to see if the new combo works better as a first treatment.
This trial tests a new drug (HRS-2189) combined with two other medications (Adebrelimab and BP102) for people whose colorectal cancer has spread. It aims to see if this combination can help control the cancer.
This trial tests whether adding two immunotherapy drugs (adebrelimab and SHR-8068) to standard chemoradiation before surgery can improve outcomes for adults with locally advanced rectal cancer that can be surgically removed.
This trial tests a new combination therapy for advanced colorectal cancer that has not responded to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.